Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate-Reference-Cited by-同舟云学术

Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate

Published:2022-01 Issue:1 Volume:11 Page:
ISSN:2050-0068
Container-title:Clinical & Translational Immunology
language:en
Short-container-title:Clin & Trans Imm

Author:

De Rosa Stephen C¹,Cohen Kristen W¹,Bonaparte Matthew²,Fu Bo³,Garg Sanjay⁴,Gerard Catherine⁵,Goepfert Paul A⁶,Huang Ying¹,Larocque Daniel⁷,McElrath M. Juliana¹,Morris Daryl¹,Van der Most Robbert⁸,Bruyn Guy⁹,Pagnon Anke⁷^ORCID

Affiliation:

1. Vaccine and Infectious Disease Division Fred Hutchinson Cancer Research Center Seattle WA USA

2. Global Clinical Immunology Sanofi Pasteur Swiftwater PA USA

3. Biostatics Sanofi Pasteur Swiftwater PA USA

4. R&D Operations Sanofi Pasteur Swiftwater PA USA

5. R&D GlaxoSmithKline Vaccines Rixensart Belgium

6. Department of Medicine University of Alabama at Birmingham Birmingham AL USA

7. Research Department Sanofi Pasteur Marcy l’Étoile France

8. Translational Science GlaxoSmithKline Vaccines Rixensart Belgium

9. Global Clinical Development Sanofi Pasteur Swiftwater PA USA

Publisher

Wiley

Subject

General Nursing,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cti2.1360

Reference48 articles.

1. Regulatory Affairs Professionals Society (RAPS).COVID‐19 vaccine tracker.2021. Available athttps://www.raps.org/news‐and‐articles/news‐articles/2020/3/covid‐19‐vaccine‐tracker. Accessed on 27 April 2021.

2. Gavi The Vaccine Alliance.Four reasons why we need multiple vaccines for Covid‐19. Available athttps://www.gavi.org/vaccineswork/four‐reasons‐why‐we‐need‐multiple‐vaccines‐covid‐19. Accessed 06 July 2021.

3. European Medicines Agency.Committee on human medicinal products: Guideline on clinical evaluation of vaccines (draft).2018. Available athttps://www.ema.europa.eu/en/documents/scientific‐guideline/draft‐guideline‐clinical‐evaluation‐vaccines‐revision‐1_en.pdf. Accessed 19 July 2021.

4. World Health Organization.Guidelines on clinical evaluation of vaccines: regulatory expectations: Revision of WHO TRS 924 Annex 1.2016. Available athttps://www.who.int/biologicals/expert_committee/Clinical_changes_IK_final.pdf. Accessed 19 July 2021.

5. Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer;Human Vaccines & Immunotherapeutics;2024-08-29

2. The use of proteins and peptides-based therapy in managing and preventing pathogenic viruses;International Journal of Biological Macromolecules;2024-06

3. Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants;Heliyon;2024-03

4. Whole blood stimulation as a tool for studying the human immune system;European Journal of Immunology;2023-12-16

5. Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development;Frontiers in Immunology;2023-11-23